FORMULATION ARTICLES
-
![Molecular structure for medical, technology, chemistry, science-GettyImages-2228457760]( "Can Making mRNA More \"Rigid\" Unlock The Next Leap In RNA Medicines?")
Can Making mRNA More "Rigid" Unlock The Next Leap In RNA Medicines?Can stabilizing mRNA structure unlock better performance? New strategies aim to “rigidify” mRNA, improving translation, stability, and manufacturability while reducing variability across conditions.
-
![Genetic engineering, Genetic testing, pharmacy, Regenerative medicine-GettyImages-1459917354]( "Rethinking The Oligonucleotide Backbone: A New Approach To RNA Therapeutic Design")
Rethinking The Oligonucleotide Backbone: A New Approach To RNA Therapeutic DesignBackbone engineering reframes RNA design, enabling programmable charge, uptake, and delivery — transforming oligonucleotides from fixed structures into tunable, multifunctional therapeutic systems.
-
![DNA, medical research-GettyImages-919410014]( "AI Foundation Models For RNA Biology")
AI Foundation Models For RNA BiologyAI foundation models are transforming RNA biology by learning sequence–structure–function relationships, enabling accurate predictions, scalable discovery, and deeper insight into RNA regulation and design.
-
![GettyImages-1410189348]( "Nanosystems And Rare Diseases: Opportunities And Limitations")
Nanosystems And Rare Diseases: Opportunities And LimitationsNanosystems offer unique capabilities, enabling researchers to design precise, versatile delivery systems that address key challenges in rare diseases.
-
![cell biology, biochemistry, cellular signaling, cell integrity-GettyImages-2196575143]( "The Potency Chains Of Events For mRNA/LNP Therapeutics")
The Potency Chains Of Events For mRNA/LNP TherapeuticsPotency in mRNA/LNP therapies depends on two chains: manufacturing/cold chain integrity and complex in vivo delivery. Breakdowns at any step — from stability to translation — can limit efficacy and safety.
-
![Global health safety regulation-GettyImages-2245658628]( "How Informal FDA Feedback Is Quietly Driving RNA Capital Allocation")
How Informal FDA Feedback Is Quietly Driving RNA Capital AllocationSubtle FDA signals — especially in pre-IND talks — are quietly shaping RNA investment. Early regulatory feedback on CMC and comparability now drives how investors assess risk and allocate capital.
FORMULATION VIDEOS
Explore constructing a modular RNA-LNP GMP facility using Cytiva's FlexFactory™ process train in a KUBio™ environment to scale RNA-LNP therapies.
CRISPR gene editing and lipid nanoparticle delivery are revolutionizing precision medicine. Discover how optimized LNP systems and advanced analytics accelerate therapeutic development.
In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their thoughts on the scientific-research and CMC-related reasons that have made the lipid nanoparticle the “darling” of the delivery world for mRNA/RNA products today.
Review strategies to assess the potential for human immune response following the administration of an mRNA therapeutic, the associated LNP, and the protein encoded for by the mRNA.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![nanoparticles-drug molecule-GettyImages-1428647836]( "Accelerate LNP Manufacturing With Automated Process Development")
Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.
-
![GettyImages-1409578453-mRNA-LNP-lipid-nanoparticle-RNA therapy]( "An Introduction And Brief History Of mRNA-LNPs")
With adjustable components and increased stability during bloodstream circulation, LNPs are significantly advancing drug development and delivery, particularly for mRNA vaccines.
-
![GettyImages-1437856375-lnp-lipid-nanoparticle]( "Nanomedicine Modalities Find Path To Clinic Through Analytics")
Lipid nanoparticles have revolutionized drug delivery, ushering in a new era of nanomedicine. Discover how advanced analytical tools are accelerating next-generation LNP therapeutics.
-
![GettyImages-1695276785 lab, vial, research]( "Comparing Microfluidic Mixing With A Turbulent Jet Approach For Lipid Nanoparticles")
A comparative study examines how two mixing technologies, microfluidic and turbulent jet, influence the attributes of lipid nanoparticles and their suitability for different stages of drug development.
-
![GettyImages-1182436133 scientist, lab, research, oncology]( "Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced Therapeutics")
Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced TherapeuticsPrecision in nanoparticle processing is key for drug delivery and vaccines. Learn how monodispersed formulations enhance reproducibility and stability for next-generation therapeutics, like RNA-LNPs.
-
![GettyImages-1409578453-mRNA-LNP-lipid-nanoparticle-RNA therapy]( "Formulation Process And Analytical Development Capabilities")
Explore process and analytical development capabilities that can help you advance your formulation to GMP Manufacturing.
-
![Outsourcing RNA Feature Image]( "Outsourcing RNA-LNP Production: A Key To Competitive Success")
Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.
